Sunday, August 31, 2014   

Janssen raises alarm on drug in Japan after 17 deaths
(04-09 19:18)

The Japanese unit of drug maker Janssen Pharmaceuticals says 17 people have died after being injected with its drug to treat schizophrenia.
Fatalities have piled up since the drug was launched in Japan last November.
The company, an affiliate of US-based Johnson and Johnson, advised medical workers to use the Paliperidone Palmitate medication with great care even though it was not known whether it had caused the deaths.
The drug, named Xeplion, is estimated to have been used by 10,700 people since November 19, according to a web notice.
The causes of the 17 deaths included cardiac infarction, pulmonary embolism and suffocation due to inhalation of vomit.
In many cases the deaths occurred about 40 days after injections of the drug.—AFP
   
Other World breaking news:
Arson attack interrupts Berlin public transport (08-29 18:24)
Greek FM jet makes safe unscheduled landing (08-29 17:21)
EU weighs Ukraine policy, Russia sanctions (08-29 17:18)
Pro-Russian rebels, Ukraine target civilians: UN (08-29 16:30)
Gold rush as artist buries bullion on UK beach (08-29 16:14)
Rob Ford facing new allegations (08-29 16:11)
Malaysia Airlines to trim staff, routes under reform plan (08-29 15:48)
Japan councilor's China drug trial ends: reports (08-29 15:23)
Dozens of planes grounded in German pilot strike (08-29 14:53)
Iceland aviation on red alert after volcanic eruption (08-29 14:35)

More breaking news >>

© 2014 The Standard, The Standard Newspapers Publishing Ltd.
Contact Us | About Us | Newsfeeds | Subscriptions | Print Ad. | Online Ad. | Street Pts

 


Home | Top News | Local | Business | China | ViewPoint | CityTalk | World | Sports | People | Central Station | Spree | Features

The Standard

Trademark and Copyright Notice: Copyright 2014, The Standard Newspaper Publishing Ltd., and its related entities. All rights reserved.  Use in whole or part of this site's content is prohibited.   Use of this Web site assumes acceptance of the
Terms of Use, Privacy Policy Statement and Copyright Policy.  Please also read our Ethics Statement.